NeuroMetrix 将来の成長

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、NeuroMetrix は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

NasdaqCM:NURO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2024	4	-8	N/A	N/A	N/A
6/30/2024	4	-8	-7	-7	N/A
3/31/2024	5	-8	-7	-7	N/A
12/31/2023	6	-7	-6	-6	N/A
9/30/2023	6	-6	-6	-6	N/A
6/30/2023	7	-5	-6	-6	N/A
3/31/2023	8	-5	-6	-6	N/A
12/31/2022	8	-4	-5	-5	N/A
9/30/2022	8	-5	-4	-4	N/A
6/30/2022	8	-4	-3	-3	N/A
3/31/2022	8	-3	-3	-3	N/A
12/31/2021	8	-2	-2	-2	N/A
9/30/2021	8	-2	-1	-1	N/A
6/30/2021	8	-1	-1	-1	N/A
3/31/2021	7	-1	-1	-1	N/A
12/31/2020	7	-2	-2	-2	N/A
9/30/2020	7	-3	-2	-2	N/A
6/30/2020	7	-4	-4	-4	N/A
3/31/2020	8	-6	-5	-5	N/A
12/31/2019	9	-4	-4	-4	N/A
9/30/2019	11	-6	-4	-4	N/A
6/30/2019	13	-3	-2	-2	N/A
3/31/2019	14	1	1	1	N/A
12/31/2018	16	0	3	3	N/A
9/30/2018	17	0	0	0	N/A
6/30/2018	17	-7	N/A	-3	N/A
3/31/2018	18	-11	N/A	-7	N/A
12/31/2017	17	-20	N/A	-13	N/A
9/30/2017	16	-20	N/A	-13	N/A
6/30/2017	16	-17	N/A	-14	N/A
3/31/2017	14	-38	N/A	-15	N/A
12/31/2016	12	-35	N/A	-15	N/A
9/30/2016	11	-43	N/A	-15	N/A
6/30/2016	10	-42	N/A	-15	N/A
3/31/2016	8	-23	N/A	-14	N/A
12/31/2015	7	-21	N/A	-13	N/A
9/30/2015	6	-13	N/A	-12	N/A
6/30/2015	5	-11	N/A	-10	N/A
3/31/2015	5	-12	N/A	-9	N/A
12/31/2014	6	-11	N/A	-8	N/A
9/30/2014	6	-12	N/A	-7	N/A
6/30/2014	5	-11	N/A	-6	N/A
3/31/2014	5	-8	N/A	-6	N/A
12/31/2013	5	-9	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: NUROの予測収益成長が貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: NUROの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: NUROの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: NUROの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: NUROの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: NUROの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

NeuroMetrix 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Second quarter 2024 earnings released: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023)

NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: US$1.67 loss per share (vs US$1.64 loss in 1Q 2023)

NeuroMetrix, Inc. has completed a Follow-on Equity Offering in the amount of $0.692831 million.

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

New major risk - Shareholder dilution

RS Fund Discloses its Views on NeuroMetrix

Full year 2023 earnings released: US$6.08 loss per share (vs US$4.96 loss in FY 2022)

NeuroMetrix, Inc. to Report Q4, 2023 Results on Feb 22, 2024

NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy

Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.23 loss in 3Q 2022)

New minor risk - Share price stability

NeuroMetrix, Inc. to Report Q3, 2023 Results on Oct 26, 2023

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

NeuroMetrix, Inc. to Report Q2, 2023 Results on Jul 27, 2023

NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia

NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting

NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

NeuroMetrix, Inc. to Report Q4, 2022 Results on Feb 23, 2023

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Insufficient new directors

NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.12 loss in 3Q 2021)

NeuroMetrix reports Q3 results

NeuroMetrix, Inc. to Report Q3, 2022 Results on Oct 20, 2022

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2021)

NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M

NeuroMetrix, Inc. to Report Q2, 2022 Results on Jul 21, 2022

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

NeuroMetrix, Inc. Reports Quell(R) Wearable Neuromodulation Device Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

Insufficient new directors

NeuroMetrix, Inc. to Report Q1, 2022 Results on Apr 26, 2022

NeuroMetrix, Inc. Reports That Quell® Wearable Neuromodulator to Be Evaluated in Post-Acute Covid-19 Syndrome

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.068 loss in 3Q 2020)

NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation

Senior VP recently sold US$528k worth of stock

Senior VP recently sold US$271k worth of stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.28 loss in 2Q 2020)

We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely

NeuroMetrix, Inc. Announces Quell Technology

NeuroMetrix Announces Top-Line Results from a Randomized Controlled Trial of Quell for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

First quarter 2021 earnings released: US$0.016 loss per share (vs US$0.45 loss in 1Q 2020)

NeuroMetrix, Inc., Annual General Meeting, Apr 27, 2021

Full year 2020 earnings released: US$0.55 loss per share (vs US$3.90 loss in FY 2019)

NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans

NeuroMetrix, Inc. to Report Q4, 2020 Results on Jan 28, 2021

New 90-day high: US$3.76

New 90-day high: US$3.05

New 90-day high: US$1.86

Third quarter earnings released

NeuroMetrix, Inc. to Report Q3, 2020 Results on Oct 22, 2020

NeuroMetrix, Inc. Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-The-Counter Pain Relief Device

New 90-day low - US$1.72

NeuroMetrix, Inc. to Report Q2, 2020 Results on Jul 23, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘